Jane Wasman Net Worth

The estimated Net Worth of Jane Wasman is at least $4.26 Milione dollars as of 2 December 2019. Ms. Wasman owns over 2,227 units of SELLAS Life Sciences Inc stock worth over $154,994 and over the last 19 years she sold SLS stock worth over $3,994,019. In addition, she makes $108,374 as Independent Chairman of the Board at SELLAS Life Sciences Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Wasman SLS stock SEC Form 4 insiders trading

Jane has made over 48 trades of the SELLAS Life Sciences Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently she sold 2,227 units of SLS stock worth $3,563 on 2 December 2019.

The largest trade she's ever made was exercising 54,536 units of SELLAS Life Sciences Inc stock on 9 February 2017 worth over $1,206,882. On average, Jane trades about 3,834 units every 52 days since 2006. As of 2 December 2019 she still owns at least 117,420 units of SELLAS Life Sciences Inc stock.

You can see the complete history of Ms. Wasman stock trades at the bottom of the page.

Jane Wasman biography

Jane Wasman J.D. serves as Independent Chairman of the Board of the Company. Ms. Wasman has been a director of the Company, Chair of the Board and Chair of the Nominating and Corporate Governance Committee of the Board since December 2017. Ms. Wasman became a member of the Audit Committee in 2019. Ms. Wasman was President, International & General Counsel and Corporate Secretary of Acorda Therapeutics, Inc., or Acorda, a publicly traded biopharmaceutical company, from October 2012 until December 2019, managing its international, legal, quality, IP and compliance functions. From January 2012 until October 2012, she was Acorda’s Chief, Strategic Development, General Counsel and Corporate Secretary, and from May 2004 until January 2012, she was Acorda’s Executive Vice President, General Counsel and Corporate Secretary. Before joining Acorda, Ms. Wasman was with Schering-Plough Corporation, a global pharmaceutical company, for over eight years, holding various U.S. and international leadership positions, including Staff Vice President and Associate General Counsel. Ms. Wasman earned a J.D. from Harvard Law School and her undergraduate degree magna cum laude from Princeton University. Ms. Wasman is also a member of the board of directors of Rigel Pharmaceuticals, Inc., a publicly traded biotechnology company and has been a member of the board of directors and of the executive committee of the board of NewYorkBIO since 2007.

What is the salary of Jane Wasman?

As the Independent Chairman of the Board of SELLAS Life Sciences Inc, the total compensation of Jane Wasman at SELLAS Life Sciences Inc is $108,374. There are 7 executives at SELLAS Life Sciences Inc getting paid more, with Angelos Stergiou having the highest compensation of $1,426,610.

How old is Jane Wasman?

Jane Wasman is 63, she's been the Independent Chairman of the Board of SELLAS Life Sciences Inc since 2017. There are 1 older and 13 younger executives at SELLAS Life Sciences Inc. The oldest executive at SELLAS Life Sciences Group Inc is David Scheinberg, 64, who is the Director.

Insiders trading at SELLAS Life Sciences Inc

Over the last 7 years, insiders at SELLAS Life Sciences Inc have traded over $74,616 worth of SELLAS Life Sciences Inc stock. The most active insiders traders include John Varian, Jane Wasman e David A Scheinberg. On average, SELLAS Life Sciences Inc executives and independent directors trade stock every 205 days with the average trade being worth of $6,842. The most recent stock trade was executed by Angelos M. Stergiou on 5 December 2022, trading 6,494 units of SLS stock currently worth $16,949.

What does SELLAS Life Sciences Inc do?

σellas life sciences is a healthcare-oriented global group of companies with a unique and innovative vision, which is ambitious, yet clear: to practice the medicine of tomorrow, today. in other words, we incorporate innovation throughout all our activities aiming at breakthroughs that will have a significant impact on the thinking and practicing of healthcare worldwide. our international team of acknowledged scientists, doctors and health professionals along with a seasoned and highly experienced pharmaceutical executive management form the core of σellas. we strive to improve patients' quality of life through developing and commercializing cutting-edge drugs, medical devices and innovative therapies.

Complete history of Ms. Wasman stock trades at Acorda Therapeutics Inc, Athersys Inc, Rigel Pharmaceuticals e SELLAS Life Sciences Inc

SELLAS Life Sciences Inc executives and stock owners

SELLAS Life Sciences Inc executives and other stock owners filed with the SEC include:

• Angelos Stergiou,
  President, Chief Executive Officer, Director
• Dr. Angelos M. Stergiou M.D., ScD h.c.,
  Founder, Pres, CEO & Director
• Barbara Wood,
  Executive Vice President, General Counsel, Corporate Secretary
• Barbara A. Wood,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Dragan Cicic M.D., MBA,
  Sr. VP of Clinical Devel.
• John Burns,
  Interim Principal Accounting Officer, Vice President - Finance, Corporate Controller
• Dr. Dragan Cicic,
  Sr. VP of Clinical Devel.
• Jane Wasman,
  Independent Chairman of the Board
• John Varian,
  Independent Director
• Robert Van Nostrand,
  Independent Director
• David Scheinberg,
  Director
• Dragan Cicic,
  Senior Vice President - Clinical Development
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Robert M. Francomano,
  Sr. VP & Chief Commercial Officer
• John Thomas Burns CPA,
  Sr. VP of Fin. & Chief Accounting Officer
• David D. Moser,
  VP of Legal Affairs
• Jörg W. Breitkopf,
  Head of Clinical Operations
• Dr. Christopher R. Shackleton,
  Director of Clinical and Bus. Operations
• Martin G. Baum,
  Chief Operating Officer
• John Thomas Burns CPA, CPA,
  VP of Fin., Corp. Controller & Chief Accounting Officer
• Fabio Lopez,
  Director
• Nicholas J. Sarlis,
  Chief Medical Officer and SVP
• Robert Francomano,
  Chief Commercial Officer
• Fabio Eqc Private Markets S...,
  
• Stephen F Ghiglieri,
  Director
• Gregory M Torre,
  CRO and SVP
• Fabio Eqc Private Markets S...,
  
• Gene Mack,
  CFO and Treasurer
• Katherine Bach Kalin,
  Director